Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling ...

Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared ...

An Ipsen-commissioned survey has identified widespread problems with the transition from pediatric to adult healthcare, ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

BeOne Medicines has tapped former professional soccer goalkeeper Tim Howard as the face of its first major corporate campaign ...

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the ...

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an ...

Even as a new drug pricing specter rears its head in President Donald Trump’s “Most Favored Nation” policies, drugmakers ...

Tarsus Pharmaceuticals has spent the past three years marketing its way out of a largely unknown but stigmatized condition: ...